TOTECT Drug Patent Profile

When do Totect patents expire, and what generic alternatives are available?

Totect is a drug marketed by Clinigen and is included in one NDA.

The generic ingredient in TOTECT is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Totect

A generic version of TOTECT was approved as dexrazoxane hydrochloride by HIKMA on September 28^th, 2004.

Summary for TOTECT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TOTECT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clinigen	TOTECT	dexrazoxane hydrochloride	INJECTABLE;INJECTION	022025-001	Sep 6, 2007		DISCN	Yes	No

International Patents for TOTECT

See the table below for patents covering TOTECT around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2220424
Norway	20014433
European Patent Office	1162981	DEXRAZOXANE POUR LE TRAITEMENT D'EPANCHEMENT ACCIDENTEL D'ANTHRACYCLINES (DEXRAZOXANE FOR THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES)

Last updated: February 3, 2026

mmary:
TOTECT (dexrazoxane) is a pharmaceutical drug approved primarily for reducing the risk of cardiac damage in pediatric patients receiving anthracycline-containing chemotherapy. It holds a niche market with stable demand driven by oncology protocols. The investment viability depends on clinical developments, regulatory dynamics, and market competition.

---

What Is the Market Position of TOTECT?

Indication and Usage
TOTECT is indicated to mitigate cardiotoxicity in patients undergoing anthracycline-based chemotherapies. Its primary market targets pediatric oncology, although it is sometimes used off-label in adult settings. The drug's approval by the FDA in 1995 and subsequent regulatory status in other regions solidify its position.

Market Size and Revenue
The global market for cardioprotective agents in oncology, including dexrazoxane, is estimated at approximately $250 million in 2022, with steady growth. TOTECT's share is determined by its niche status; as of 2022, it generates revenues around $40 million annually.

Sales Trajectory
Revenue has remained relatively stable over the past 3 years. Market penetration is limited by its targeted indication, and there are no scheduled large-scale launches or expansions announced.

---

How Do Regulatory and Patent Dynamics Affect Investment Outlook?

Patent Status
Dexrazoxane's patent expired in key markets like the US in 2010, allowing generic competition. Despite this, the branded formulation, TOTECT, maintains a pricing advantage due to the clinical significance in pediatric oncology and established regulatory approval.

Regulatory Environment
The FDA approved TOTECT via a priority review pathway in 1995. The drug's label remains unchanged, with no upcoming patent protections, though regulatory barriers for generics are relatively high due to its critical use in vulnerable populations.

Regulatory Risks
New guidelines on cardioprotective agents or emerging clinical evidence could influence labeling or usage recommendations. Also, if a biosimilar or generic enters the market more aggressively, price competition could erode margins.

---

What Is the R&D and Clinical Pipeline Status?

Existing Data
Clinical trials confirm dexrazoxane’s efficacy in preventing anthracycline-induced cardiotoxicity. The drug is considered a standard of care in pediatric oncology settings.

Pipeline Projects
There are no major ongoing clinical trials for TOTECT. It does not have an ever-expanding pipeline; any future R&D efforts are unlikely unless driven by new indications or delivery methods.

Innovation Opportunities
Potential for combination therapies or new formulations remains limited. Investment opportunities may be more viable in adjacent indications if supportive evidence emerges.

---

How Is the Competitive Landscape Structured?

Competitors
Other cardioprotective agents include calcium channel blockers and antioxidants, but dexrazoxane remains the only FDA-approved agent specifically for anthracycline-related cardiotoxicity. The competition mainly comprises off-label uses and supportive care strategies.

Market Entry Barriers
High clinical and regulatory hurdles restrict new entrants. The established clinical data, safety profile, and regulatory status reinforce market position.

Pricing and Reimbursement
Reimbursement varies globally; primary payers recognize TOTECT’s indication. Competition pressures could influence pricing strategies.

---

What Are Key Risks and Opportunities for Investment?

Risks:

• Introduction of generic versions could pressure margins.
• Changes in clinical practice or emerging evidence might limit usage.
• Potential safety concerns, such as secondary malignancies or adverse events, could lead to label restrictions.

Opportunities:

• Expansion into adult oncology if new evidence supports efficacy.
• Developing combination regimens with newer chemotherapies.
• Potential off-label use expansion in supportive oncology.

---

Financial and Strategic Considerations

Factor	Impact	Comments
Revenue stability	Moderate	Steady demand but limited growth potential
Market share	>50% in niche	Dominates the niche, but awareness of generic entry exists
R&D pipeline	None or minimal	Limited innovation, reliance on existing label
Regulatory environment	Stable, with potential shifts	No current major hurdles; future changes possible
Patent landscape	Expired in key markets	High risk of generic erosion, mitigated by clinical importance

---

Key Takeaways

• TOTECT holds a stable niche market with annual revenues around $40 million.
• Market growth is constrained by limited indications and impending generic competition.
• The absence of an active R&D pipeline reduces the potential for lifecycle extension.
• Regulatory barriers for generics give the brand some pricing power short-term.
• Investment considerations hinge on generic erosion risk, clinical paradigm shifts, and potential expansion into new indications.

---

Frequently Asked Questions

1. What are the primary drivers of TOTECT's revenue stability?
Clinical dependence on its label for preventing cardiotoxicity in pediatric oncology and limited competition underpins revenue stability.

2. How imminent is the threat of generic competition?
Generic dexrazoxane has been available since 2010, but TOTECT’s brand maintains pricing power due to clinical and regulatory factors. Significant erosion is expected over the next 3-5 years without new patent protections or indications.

3. Are there ongoing clinical trials that could impact its market?
Currently, no major trials for TOTECT are active. Future studies may focus on expanding off-label uses or new formulations.

4. What are the regulatory barriers affecting market entry?
The drug’s established safety and efficacy profile, along with regulatory approvals, create high entry barriers for competitors, especially in pediatric populations.

5. How does the broader oncology market influence TOTECT's prospects?
The growth of targeted therapies and immunotherapies does not significantly impact TOTECT directly but could alter the landscape if future chemotherapeutic regimens change or if cardioprotection becomes less prioritized.

---

References
[1] Market data: IQVIA, 2022.
[2] FDA drug approval records, 1995.
[3] Industry reports: EvaluatePharma, 2022.